(Total Views: 114)
Posted On: 12/16/2024 8:24:39 AM
Post# of 580
I sense a positive sentiment in the coming FDA administration.
“The administration is expected to usher in a new era of a less restrictive FTC, which will likely result in increased M&A activity ,” Baird senior research analyst Mike Perrone told BioSpace by email. This, he added, would be most welcome, noting that 2024 is “the first year in recent memory that has not seen a biopharma transaction above $5B in value. . . . Ultimately any increase in large biopharma M&A would be a boost to MID cap biotech valuations. ”
https://www.biospace.com/business/trump-admin...-biopharma
$5-$10+
“The administration is expected to usher in a new era of a less restrictive FTC, which will likely result in increased M&A activity ,” Baird senior research analyst Mike Perrone told BioSpace by email. This, he added, would be most welcome, noting that 2024 is “the first year in recent memory that has not seen a biopharma transaction above $5B in value. . . . Ultimately any increase in large biopharma M&A would be a boost to MID cap biotech valuations. ”
https://www.biospace.com/business/trump-admin...-biopharma
$5-$10+
(0)
(0)
